“Gilead Sciences Inc has settled patent disputes with five drugmakers over proposed generic versions of its blockbuster HIV drugs Descovy and Odefsey and hepatitis B drug Vemlidy, it said Monday in a filing with the U.S. Securities and Exchange Commission.

Generic drugmakers Apotex Inc, Lupin Ltd, Cipla Ltd, Macleods Pharmaceuticals Ltd and Hetero Labs Ltd will receive non-exclusive licenses to the patents, allowing them to sell generic versions of the HIV drugs starting in October 2031 and Vemlidy in January 2032, according to the filing.”

Director Dennies Varughese, Pharm.D., and Associate Joseph H. Kim are mentioned as Hetero Labs’ representation in the article “Gilead Settles Patent Fight With Generic Drugmakers Over HIV Drugs,” published by Reuters.

© 2022 Reuters